Although this is the same mechanism that led to questioning continued ACEi/ARB treatment during the acute phase of SARS-CoV-2 infection, enhanced lung membrane ACE2 expression during the sub-acute phase is now hypothesized to prevent COVID-19–induced cytokine storm and reduce ARDS (Gil et al., 2020; McKee et al., 2020). This evidence concerns the gene ACE2 and COVID-19.